L’ incidenza di neutropenia febbrile era inferiore nei pazienti randomizzati a ricevere pegfilgrastim rispetto al placebo (1% versus 17%, p < 0,001). ###>The incidence of febrile neutropenia was lower for patients randomised to receive pegfilgrastim compared with placebo (1% versus 17%, p < 0.001).